Thiosuccinyl-crosslinked Hemoglobin Analogs and Methods of Use and Preparation Thereof

A thiosuccinyl-crosslinked hemoglobin comprising a tetrameric hemoglobin and at least one thiosuccinyl crosslinking moiety of Formula 1:

• or a pharmaceutically acceptable salt or zwitterion thereof, wherein
• each N* independently represents a nitrogen selected from the group consisting of a nitrogen in a lysine residue side chain in the tetrameric hemoglobin and a nitrogen at a N-terminus in the tetrameric hemoglobin;
• and
• R1 is alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, or —(CR2)nY, wherein n is an integer selected from 0-10;
• R for each instance is independently hydrogen, alkyl, aralkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
• or two instances of R taken together form a 3-6 membered cycloalkyl or heterocycloalkyl containing 1, 2, or 3 heteroatoms selected from N, O, and S;
• and Y is selected from the group consisting of OR4, SR4, N(R4)2, —(C═O)R4, —(C═O)OR4, —O(C═O)R4, —O(C═O)OR4, —(C═O)N(R4)2, —(NR4)(C═O)R4, —(NR4)(C═O)OR4, —O(C═O)N(R4)2, —O(C═NR4)N(R4)2, —(NR4)(C═O)N(R4)2, —(C═NR4)N(R4)2, —(NR4)(C═NR4)N(R4)2, —(S═O)R4, —S(O)2R4, —S(O)2OR4, —S(O)2N(R4)2, —OS(O)2R4, —(NR4)S(O)2R4, —OS(O)2OR4, —OS(O)2N(R4)2, —(NR4)S(O)2N(R4)2, —(NR4)S(O)2OR4, and —(CRR2R3), wherein R2 is hydrogen, alkyl, aralkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, OR4, SR4, N(R4)2, —(C═O)R4, —(C═O)OR4, —O(C═O)R4, —O(C═O)OR4, —(C═O)N(R4)2, —(NR4)(C═O)R4, —(NR4)(C═O)OR4, —O(C═O)N(R4)2, —O(C═NR4)N(R4)2, —(NR4)(C═O)N(R4)2, —(C═NR4)N(R4)2, —(NR4)(C═NR4)N(R4)2, —(S═O)R4, —S(O)2R4, —S(O)2OR4, —S(O)2N(R4)2, —OS(O)2R4, —(NR4)S(O)2R4, —OS(O)2OR4, —OS(O)2N(R4)2, —(NR4)S(O)2N(R4)2, or —(NR4)S(O)2OR4;
• R3 is hydrogen, alkyl, aralkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, OR4, SR4, N(R4)2, —(C═O)R4, —(C═O)OR4, —O(C═O)R4, —O(C═O)OR4, —(C═O)N(R4)2, —(NR4)(C═O)R4, —(NR4)(C═O)OR4, —O(C═O)N(R4)2, —O(C═NR4)N(R4)2, —(NR4)(C═O)N(R4)2, —(C═NR4)N(R4)2, —(NR4)(C═NR4)N(R4)2, —(S═O)R4, —S(O)2R4, —S(O)2OR4, —S(O)2N(R4)2, —OS(O)2R4, —(NR4)S(O)2R4, —OS(O)2OR4, —OS(O)2N(R4)2, —(NR4)S(O)2N(R4)2, or —(NR4)S(O)2OR4;
• and
• R4 for each instance is independently selected from the group consisting of hydrogen, alkyl, aralkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
• or R1 is a moiety selected from the group consisting of:
• and
• N5-(1-((carboxymethyl)amino)-1-oxo-3λ3-propan-2-yl)glutamine or a pharmaceutically acceptable salt thereof, wherein m is a whole number selected from 1-1000.